DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Morgan Stanley - 2 Goldman Sachs - 2 it's - 2 Eli Lilly - 2 Lilly - 2 Lilly's - 2 Goldman Sachs downgrades Morgan Stanley - 1 Goldman - 1
Top related locs:
Novo Canaan Williams Sonoma 2030E U.S New York GLP
Top related orgs:
JPMorgan - 2 Nvidia - 2 ~$ - 2 Novo Nordisk - 2 NASDAQ - 1 Viking Therapeutics - 1 Citi - 1 Apollo Global Citi - 1

Search resuls for: "orals"


5 mentions found


☆ Here are Wednesday's biggest analyst calls: Nvidia, Apple, Spotify, Arm, Robinhood, Alphabet, Shopify, Disney & more
  + stars: | 2024-09-11 | by ( Michael Bloom | ) www.cnbc.com   time to read: +6 min
Here are Wednesday's biggest calls on Wall Street: Goldman Sachs downgrades Morgan Stanley to neutral from buy Goldman said it sees better value elsewhere than Morgan Stanley. Goldman Sachs upgrades Evercore to buy from neutral Goldman said the investment banking firm is "best in class." JPMorgan reiterates Nvidia as overweight JPMorgan said stocks such as Nvidia are "strong beneficiaries in the emerging AI arms race." Morgan Stanley reiterates Arm as a top pick Morgan Stanley said it's sticking with its overweight rating on the semiconductor chip company. Bank of America reiterates Apple as buy Bank of America said it's standing by its buy rating on shares of Apple.
Persons: Goldman Sachs downgrades Morgan Stanley, Goldman, Morgan Stanley, Goldman Sachs, Rosenblatt, Canaan, Jefferies, Williams, Guggenheim, it's, orals, it's bullish, Bernstein, Robinhood, Wells, Shopify, Truist, Wolfe Organizations: NASDAQ, JPMorgan, Viking Therapeutics, Citi, Apollo Global Citi, APO, U.S, " Bank of America, Novartis, Bank of America, Nvidia, Apple, Spotify, Disney, AES, ~$ Locations: Canaan, Williams, Sonoma, 2030E
☆ Gilead’s twice-yearly shot to prevent HIV succeeds in late-stage trial
  + stars: | 2024-06-20 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com   time to read: +3 min
Gilead 's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday. The results bring Gilead one step closer to introducing a new form of pre-exposure prophylaxis, or PrEP, and broadening its HIV business. If those results are positive, the company could bring lenacapavir for PrEP to market as soon as late 2025. RBC Capital Markets analyst Brian Abrahams expects Gilead's shot will significantly increase the number of people interested in preventive HIV medicine. In its statement disclosing the lenacapavir trial results Thursday, Gilead said it plans to share an update on how it plans to address access in such countries where people suffer high incidence rates of HIV.
Persons: Gilead, Jared Baeten, Gilead's Truvada, Bruce Richman, Tim Oliver, they'd, Brian Abrahams, Gilead's, — CNBC's Leanne Miller Organizations: Food and Drug Administration, PrEP, Centers for Disease Control, Prevention, Health, FDA, RBC Capital Locations: U.S, New York
☆ Cramer ranks each of the Magnificent Seven's latest quarters
  + stars: | 2024-02-21 | by ( Julie Coleman | ) www.cnbc.com   time to read: +1 min
As the first earnings season of 2024 draws to a close, CNBC's Jim Cramer gave his take on the most recent reports from the Magnificent Seven mega caps, awarding particular kudos to Nvidia and Amazon . He first lauded Nvidia, which reported record revenue up 265% thanks to continued high demand for its artificial intelligence products. He then called Amazon "the most definitive summa of all," with a hot advertising business and growing web services sector. Cramer also awarded Meta a "summa," praising its advertising capabilities and WhatsApp business. And Tesla earned a "gentleman's C," Cramer said, uncertain about how this year will shape up for the company.
Persons: CNBC's Jim Cramer, Cramer, Apple, Tesla Organizations: Nvidia, Amazon, Meta, Microsoft
☆ Here are 5 anti-obesity drug stocks besides Novo Nordisk and Eli Lilly to watch into year-end
  + stars: | 2023-10-29 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +11 min
Novo Nordisk and Eli Lilly reign over the anti-obesity drug market, and don't expect this duopoly to end soon, analysts say. All this goes on amid robust demand for Novo's semaglutide, which is sold as Ozempic for type 2 diabetes and as Wegovy for weight loss, and Lilly's tirzepatide, which hopes to receive regulatory approval for weight loss this year. Orforglipron is an oral drug Eli Lilly is developing. It has several other compounds in the pipeline, but Suvannavejh expects the weight loss drug to receive increased attention. "This range would also be competitive with LLY's orforglipron [an oral GLP-1 drug] weight loss at day 28," Smith said.
Persons: Eli Lilly, Piper Sandler, Yasmeen Rahimi, Cantor Fitzgerald, Louise Chen, Lilly, Lilly's, Chen, Price, Kyle Rasbach, We've, Rasbach, Altimmune Altimmune, NASH, Piper's, Rahimi, Cantor's Chen, it's, Eli Lilly's Mounjaro, Goldman Sachs, Chris Shibutani, David Risinger, Risinger, Jonathan Wolleben, Wolleben, Orforglipron, Graig Suvannavejh, Suvannavejh, Thomas Smith, LLY's, Smith, Yale Jen, Jen Organizations: Novo Nordisk, Pfizer, Novo, pharma, Pfizer Pfizer, danuglipron, Therapeutics, Leerink, Mizuho Securities, Viking Therapeutics Viking Therapeutics, Laidlaw & Co Locations: Novo, GLP, Eventide
☆ Eli Lilly's weight loss drugs trounce sky-high expectations, boosting the stock
  + stars: | 2023-06-27 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +5 min
What's more, some showed no signs their weight loss was leveling off, suggesting they could continue to shed pounds. (Both use semaglutide, but Ozempic is marketed as a type 2 diabetes treatment, while Wegovy is primarily for weight loss.) Bank of America's Geoff Meacham said retatrutide "exceeded expectations" for weight loss. "This is important, as while the overall 22.4% weight loss was impressive, looking at men and women separately, weight loss was 21.9% and 28.5%, respectively, with the slope in females not yet plateauing. Schott also described the weight loss as "impressive" and said it will likely compare favorably with Novo's next-generation drug CagriSema, which is expected to show weight loss of more than 25% when it releases its next update.
Persons: Eli Lilly, What's, Lilly, Lilly's, Carter Gould, Gould, orforglipron, Bank of America's Geoff Meacham, retatrutide, Meacham, Chris Schott, Schott, Novo's, Evan David Seigerman, Seigerman, Morgan Stanley, Terence Flynn, — CNBC's Michael Bloom Organizations: American Diabetes Association, Wall, Novo Nordisk, Barclays, Bank of America's, JPMorgan, Lilly, BMO Capital, Indianapolis, ~$ Locations: Novo
0 next >>
Total: 5